The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Unmet needs in the treatment of myelofibrosis: strategies to address anemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the unmet need of treating anemia in patients with myelofibrosis. Prof. Rinaldi notes the limitations of current treatment options and advises that switching JAK inhibitors could be effective in certain patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Anemia is an unmet need in myelofibrosis. As I mentioned before, you know, a large proportion of patients are anemic, either at diagnosis or after a period of time of treatment with ruxolitinib. We currently support those patients with either agents that are available in the clinic, such as erythropoietin-stimulating agents, EPO, which works in a small proportion of patients, and then we still have a problem...
Anemia is an unmet need in myelofibrosis. As I mentioned before, you know, a large proportion of patients are anemic, either at diagnosis or after a period of time of treatment with ruxolitinib. We currently support those patients with either agents that are available in the clinic, such as erythropoietin-stimulating agents, EPO, which works in a small proportion of patients, and then we still have a problem. Sometimes it’s about managing the dose of JAK inhibitors. Sometimes it’s about changing JAK inhibitors. In the UK, we have approved momelotinib for patients with anemia in myelofibrosis, which is a very effective drug. It does help and improve hemoglobin and platelets in a certain proportion of patients. But there are currently many molecules in the pipeline or in clinical trials that are trying to target that. So I think, you know, there’s going to be quite a few changes in the future, which is exciting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
